Tag Archives: Monash Institute of Pharmaceutical Sciences

Stress reducing drugs slow cancer

Anti-stress drugs slow the spread of cancer in the body say Monash Institute of Pharmaceutical Sciences (MIPS) researchers. Associate Professor Erica Sloan and senior anaesthetist and PhD student Dr Jonathan Hiller, working with teams from the Peter MacCallum Cancer Centre (PMCC), identified that beta-blockers stop cancer cells spreading through the …

Read More »

Concern over opioid use

New research by the Centre of Medicine Use and Safety (CMUS) at the Monash Institute of Pharmaceutical Sciences has found that weak opioid use is often associated with transition to stronger opioids or higher doses. The researched, which was published in leading journal, Addiction, revealed that more than one in …

Read More »

Potential treatment uncovered for chronic disease

A recent study published in Nature has revealed that a protein compound called IC7Fc has the potential to improve glucose metabolism, prevent weight gain and loss of muscle mass. The study suggests that this compound could therefore become an effective treatment for chronic conditions, including diabetes, obesity and loss of …

Read More »

Can new polymyxin antibiotic tackle superbugs?

The development of the new polymyxin is needed to meet an increasingly urgent healthcare need and Monash University today announced the grant of an exclusive licence of its portfolio of proprietary synthetic polymyxin antibiotics to a US-based biopharmaceutical company. The company, Qpex Biopharma is focused on developing new antibiotics to …

Read More »